About Us

Targeting Undruggable Cancer Targets with RNA Therapeutics

At Flamingo, we understand drug development – and more importantly – we understand RNA therapeutic drug development.  We know that robust and novel backbone chemistry is paramount when developing any RNA therapeutic, especially for difficult to treat cancers, where many modalities have failed to succeed.  Our company was built upon our deep experience and know-how in this space and we are well-positioned to advance candidates against targets considered “undruggable” by conventional chemistries.

Flamingo has the most advanced antisense RNA-targeting oncology portfolio with three clinical programs targeting undruggable transcription factors and splice variants. We also have a proprietary discovery engine, FLAME™ (Flamingo LncRNA Antisense Mining Engine), that addresses lncRNAs, a large and untapped class of disease-causing targets within the “dark matter” of the human genome.  The Company was founded in 2020 based on pioneering work in the field of lncRNAs in oncology with our academic partners at VIB, KU Leuven, Ghent University and The University of Michigan.  Flamingo has a strategic partnership with Ionis Pharmaceuticals and is supported by well-known biotechnology investors Kurma Partners and PMV.   The company is headquartered in Belgium with additional operations in San Diego, CA

Leadership

Mike Garrett
Chief Executive Officer
and Co-founder
Floor Stam
Chief Operating Officer
Rob MacLeod
Chief Scientific Officer
Michel Janicot
Vice President, Research

Board of Directors

Christopher K. Mirabelli, Ph.D.
Executive chairman
Remi Droller
Kurma Partners
Griet Vanpoucke
VIB
Tine Bekaert
PMV
Frank Bennett
CSO, Ionis
Mike Garrett
CEO

Scientific Advisors

Jean Christophe Marine, Ph.D.
Pieter Mestdagh, Ph.D.
Arul M. Chinnaiyan, M.D., Ph.D.
Hagop Youssoufian, M.D.

Partners and Investors

Flamingo was founded in 2020 based on pioneering work in the field of lncRNAs in oncology with our academic partners at VIB-KU Leuven, University of Michigan, and University of Ghent.  We have a strategic partnership with Ionis Pharmaceuticals, the leader in RNA-targeted therapy, and we are proud to be supported by well-known biotechnology investors.